Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 14/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 7/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893043 | 0.83 | PTGER2 (0.43) | PTGER2PTGER3PTGER4PTGDR | |
| SCHEMBL16480399 | 0.82 | CCNA2 (0.40) | PTGER2PTGER3MDM2POLBSMN1; SMN2 | |
| SCHEMBL9103377 | 0.80 | PHGDH (0.41) | PTGER2PTGER3SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9103390 | 0.80 | PHGDH (0.41) | PTGER2PTGER3SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9893019 | 0.79 | PTGER2 (0.37) | PTGER2PTGER3PTGER4PTGDRMAP4K1 | |
| SCHEMBL9891744 | 0.79 | SMN1; SMN2 (0.38) | PTGER2PTGER3MDM2PTGDRPOLB | |
| SCHEMBL9893023 | 0.76 | PER2 (0.46) | PTGER2PTGER3PTGDRMAP4K1ALDH1A1 | |
| SCHEMBL9893157 | 0.76 | PTGER2 (0.42) | PTGER2PTGER3PTGER4PTGDRMAP4K1 | |
| SCHEMBL6789962 | 0.76 | PTGER2 (0.49) | PTGER2PTGER3PTGER4PTGDRPOLB | |
| SCHEMBL9892975 | 0.75 | PTGER2 (0.44) | PTGER2PTGER3PTGER4PTGDRSRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | PTGER2 186/4885PTGER3 200/4885PTGER4 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.